- Home
- TRMD vs IRON Comparison
TRMD vs IRON Comparison
Compare TRMD & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- IRON
- Stock Information
- Founded
- TRMD 1889
- IRON 2017
- Country
- TRMD United Kingdom
- IRON United States
- Employees
- TRMD N/A
- IRON N/A
- Industry
- TRMD Marine Transportation
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- TRMD Consumer Discretionary
- IRON Health Care
- Exchange
- TRMD Nasdaq
- IRON Nasdaq
- Market Cap
- TRMD 1.9B
- IRON 1.9B
- IPO Year
- TRMD N/A
- IRON N/A
- Fundamental
- Price
- TRMD $20.39
- IRON $58.25
- Analyst Decision
- TRMD Buy
- IRON Strong Buy
- Analyst Count
- TRMD 1
- IRON 10
- Target Price
- TRMD $48.00
- IRON $73.70
- AVG Volume (30 Days)
- TRMD 1.4M
- IRON 267.1K
- Earning Date
- TRMD 03-06-2025
- IRON 11-12-2024
- Dividend Yield
- TRMD 23.54%
- IRON N/A
- EPS Growth
- TRMD N/A
- IRON N/A
- EPS
- TRMD 7.70
- IRON N/A
- Revenue
- TRMD $1,641,593,000.00
- IRON N/A
- Revenue This Year
- TRMD N/A
- IRON N/A
- Revenue Next Year
- TRMD N/A
- IRON N/A
- P/E Ratio
- TRMD $2.77
- IRON N/A
- Revenue Growth
- TRMD 3.90
- IRON N/A
- 52 Week Low
- TRMD $17.77
- IRON $25.60
- 52 Week High
- TRMD $40.47
- IRON $77.60
- Technical
- Relative Strength Index (RSI)
- TRMD 46.59
- IRON 40.61
- Support Level
- TRMD $20.53
- IRON $57.09
- Resistance Level
- TRMD $23.20
- IRON $61.08
- Average True Range (ATR)
- TRMD 0.70
- IRON 2.83
- MACD
- TRMD 0.24
- IRON -0.58
- Stochastic Oscillator
- TRMD 35.25
- IRON 14.04
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Exhaust segment.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.